주의력결핍 과잉행동장애(ADHD) 임상시험 현황 : 동향과 분석(2026년판)

Global Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trials Landscape is projected to register a strong CAGR during the forecast period (2026-2035).

The global attention deficit hyperactivity disorder (ADHD) clinical trials analysis market is expanding steadily as pharmaceutical companies, biotechnology firms, academic institutions, and contract research organizations intensify research efforts to develop safer, more effective, and longer-lasting therapies for ADHD. Clinical trial analysis has become an essential component of the ADHD drug development ecosystem, providing comprehensive intelligence on ongoing and completed studies, pipeline assets, trial outcomes, regulatory progress, patient recruitment, competitive benchmarking, and emerging therapeutic innovations. As the understanding of ADHD continues to evolve across pediatric, adolescent, and adult populations, demand for detailed clinical development intelligence is increasing.

ADHD remains one of the most common neurodevelopmental disorders worldwide, affecting both children and adults. Although stimulant medications continue to represent the standard of care, limitations including adverse effects, abuse potential, variable treatment response, and poor long-term adherence have encouraged developers to investigate novel pharmacological and non-pharmacological interventions. Current clinical research includes next-generation stimulants, non-stimulant therapies, digital therapeutics, neurostimulation devices, behavioral interventions, cognitive training programs, and precision medicine approaches designed to improve patient outcomes while minimizing safety concerns.

Clinical trial methodologies are also undergoing significant transformation. Decentralized clinical trials, wearable monitoring technologies, electronic patient-reported outcomes, artificial intelligence-assisted recruitment, digital biomarkers, and remote patient monitoring are improving study efficiency and patient participation. These innovations generate large volumes of clinical data that require advanced analytical platforms capable of evaluating efficacy, safety, treatment adherence, and long-term outcomes across diverse patient populations.

Growing awareness of adult ADHD, expanding diagnosis rates, increased regulatory support for innovative neuropsychiatric therapies, and rising investment in neuroscience research continue to strengthen the global ADHD clinical development landscape. As the therapeutic pipeline expands across both pharmacological and digital interventions, demand for comprehensive clinical trial analysis is expected to increase throughout the forecast period.

Market Drivers

Expanding ADHD Therapeutic Pipeline

The number of investigational therapies for ADHD continues to increase as developers pursue treatments with improved efficacy, longer duration of action, reduced abuse potential, and better tolerability.

Pipeline expansion is generating demand for comprehensive monitoring of clinical progress, regulatory developments, trial outcomes, and competitive positioning.

Increasing ADHD Diagnosis Across Age Groups

Improved awareness of ADHD among healthcare professionals and the public has increased diagnosis across pediatric and adult populations.

Growing recognition of adult ADHD has expanded patient recruitment opportunities and increased the number of clinical development programs targeting broader patient populations.

Innovation Beyond Conventional Stimulants

Developers are investigating non-stimulant medications, extended-release formulations, selective neurotransmitter modulators, digital therapeutics, neurostimulation technologies, and behavioral interventions.

Diversification of therapeutic approaches is increasing both the complexity and value of clinical trial analysis.

Adoption of Digital Clinical Technologies

Artificial intelligence, wearable devices, mobile health applications, electronic clinical outcome assessments, and decentralized trial platforms are improving clinical trial efficiency.

Digital technologies enhance patient recruitment, retention, data quality, and long-term monitoring while supporting more patient-centric trial designs.

Rising Investment in Neuroscience Research

Governments, pharmaceutical companies, biotechnology firms, and research institutions continue to increase investment in neurodevelopmental disorder research.

Growing financial support is accelerating early-stage discovery programs, multicenter clinical trials, and development of innovative ADHD therapies.

Market Restraints

Recruitment and Patient Retention Challenges

Long-duration ADHD studies often experience recruitment difficulties and patient dropout, particularly among pediatric populations.

Maintaining long-term treatment adherence and consistent follow-up remains a challenge for many clinical development programs.

High Development Costs

Large multicenter studies, long follow-up periods, extensive safety monitoring, and regulatory requirements significantly increase the cost of ADHD clinical research.

These financial requirements may limit participation by smaller biotechnology companies.

Heterogeneous Patient Population

ADHD presents with varying symptom severity, age-specific manifestations, and frequent psychiatric comorbidities.

Clinical heterogeneity complicates patient stratification, endpoint selection, and interpretation of treatment outcomes.

Technology and Segment Insights

By Trial Phase

Phase II clinical trials represent a significant portion of the ADHD development pipeline as developers evaluate efficacy, optimal dosing, safety profiles, and pharmacokinetic characteristics of investigational therapies.

Phase III studies continue to expand as promising candidates progress toward regulatory approval, while Phase I programs introduce innovative compounds utilizing novel mechanisms of action.

By Therapy Type

Pharmacological therapies remain the largest segment of ADHD clinical development. Investigational treatments include stimulant medications, selective norepinephrine reuptake inhibitors, alpha-2 adrenergic agonists, dopamine modulators, and novel non-stimulant compounds designed to improve efficacy and safety.

Non-pharmacological interventions are experiencing rapid growth through behavioral therapy, cognitive training, neurofeedback, digital therapeutics, wearable technologies, and neuromodulation devices. These approaches are increasingly evaluated either as standalone treatments or in combination with medication.

By Study Design

Randomized controlled trials continue to dominate ADHD clinical development due to regulatory requirements for demonstrating treatment efficacy and safety.

Decentralized clinical trials are becoming increasingly common through integration of telemedicine, remote assessments, wearable monitoring devices, and electronic patient-reported outcomes that improve operational efficiency and patient participation.

By End User

Pharmaceutical companies represent the largest end-user segment due to ongoing investment in ADHD drug discovery, clinical development, regulatory submission, and commercialization.

Biotechnology companies utilize clinical trial analysis to evaluate pipeline assets, attract investment, and establish strategic collaborations.

Academic institutions, contract research organizations, healthcare consulting firms, and government research agencies also rely extensively on ADHD clinical trial intelligence to support scientific research and development planning.

Regional Insights

North America dominates the global ADHD clinical trials analysis market due to its advanced clinical research infrastructure, strong pharmaceutical industry, extensive neuroscience research, and favorable regulatory environment. The region hosts a large proportion of global ADHD clinical trials and continues to lead therapeutic innovation.

Europe represents a major market supported by collaborative academic research, well-established pharmaceutical companies, and increasing investment in neurodevelopmental disorder research. Countries including Germany, the United Kingdom, France, Italy, and Spain remain active participants in multinational ADHD clinical studies.

Asia Pacific is expected to witness the fastest growth during the forecast period. Improving clinical research infrastructure, expanding pharmaceutical investment, increasing ADHD awareness, and greater participation in multinational clinical programs are strengthening research activity across China, Japan, India, South Korea, and Australia.

Latin America and the Middle East & Africa are gradually expanding their participation in ADHD clinical research through healthcare modernization, increasing clinical trial capacity, and greater collaboration with international pharmaceutical organizations.

Competitive and Strategic Outlook

The global ADHD clinical trials analysis market is characterized by participation from pharmaceutical companies, biotechnology firms, clinical research organizations, healthcare analytics providers, and specialized market intelligence companies. Competition increasingly focuses on delivering comprehensive clinical intelligence covering pipeline analysis, trial benchmarking, regulatory tracking, patient recruitment trends, biomarker development, and competitive positioning.

Artificial intelligence, predictive analytics, natural language processing, and real-world evidence platforms are becoming important differentiators among clinical intelligence providers. Organizations are investing in automated clinical data extraction, advanced statistical analysis, and digital trial monitoring to improve decision-making across the drug development lifecycle.

Strategic collaborations between pharmaceutical companies, research institutions, technology providers, and contract research organizations continue to accelerate innovation while improving trial efficiency. Future competition is expected to focus on decentralized trial technologies, digital biomarkers, precision medicine approaches, and integrated analytics platforms capable of supporting increasingly complex ADHD clinical development programs.

Conclusion

The global ADHD clinical trials analysis market is positioned for sustained growth as research activity continues to expand across pharmacological, digital, and behavioral therapeutic approaches. Rising ADHD diagnosis rates, increasing investment in neuroscience research, technological advances in clinical trial management, and diversification of therapeutic pipelines are expected to drive market expansion throughout the forecast period. Although challenges related to recruitment, development costs, and patient heterogeneity remain, continued innovation in clinical trial design and data analytics will strengthen the efficiency and effectiveness of ADHD therapeutic development.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Report Scope and Objectives
• 1.2 ADHD Clinical Development Landscape Snapshot
• 1.3 Current Pipeline Size and Maturity Overview
• 1.4 Key Clinical and Commercial Insights
• 1.5 Emerging Therapeutic Trends
• 1.6 Major Strategic Developments
• 1.7 High-Value Pipeline Opportunities
• 1.8 Key Risks and Development Challenges
• 1.9 Analyst Perspective and Future Outlook

2. Pipeline Overview

• 2.1 ADHD Pipeline Introduction
• 2.2 Pipeline Definition and Inclusion Criteria
• 2.3 Overview of ADHD Drug Development Ecosystem
• 2.4 Historical Evolution of ADHD Therapeutics
• 2.5 Current Pipeline Asset Distribution
  • 2.5.1 Pipeline Assets by Development Phase
  • 2.5.2 Pipeline Assets by Therapeutic Modality
  • 2.5.3 Pipeline Assets by Mechanism of Action
  • 2.5.4 Pipeline Assets by Route of Administration
  • 2.5.5 Pipeline Assets by Molecule Type
• 2.6 Pipeline Maturity Analysis
• 2.7 Historical Pipeline Growth Trends
• 2.8 Pipeline Attrition Trends
• 2.9 Emerging Pipeline Themes
• 2.10 Innovation Intensity Assessment

3. Disease and Unmet Need Analysis

• 3.1 ADHD Disease Overview
  • 3.1.1 Definition and Classification
  • 3.1.2 Diagnostic Criteria and Clinical Presentation
  • 3.1.3 ADHD Subtypes
  • 3.1.4 Comorbid Conditions
• 3.2 Epidemiology Overview
  • 3.2.1 Prevalence Trends
  • 3.2.2 Incidence Trends
  • 3.2.3 Age-wise Patient Distribution
  • 3.2.4 Gender-based Epidemiology
• 3.3 Disease Burden Assessment
  • 3.3.1 Clinical Burden
  • 3.3.2 Social Burden
  • 3.3.3 Economic Burden
• 3.4 Current Treatment Paradigm
  • 3.4.1 Pharmacological Therapies
  • 3.4.2 Behavioral and Non-pharmacological Therapies
  • 3.4.3 Treatment Algorithms
• 3.5 Limitations of Existing Therapies
  • 3.5.1 Safety Concerns
  • 3.5.2 Abuse Potential and Dependence Risks
  • 3.5.3 Adherence Challenges
  • 3.5.4 Long-term Efficacy Issues
• 3.6 Key Unmet Needs
  • 3.6.1 Pediatric Population Needs
  • 3.6.2 Adolescent Population Needs
  • 3.6.3 Adult ADHD Treatment Gaps
  • 3.6.4 Non-stimulant Therapy Opportunities
  • 3.6.5 Precision Medicine Opportunities

4. Mechanism and Modality Landscape

• 4.1 Mechanistic Overview of ADHD Drug Development
• 4.2 Neurobiological Targets in ADHD
• 4.3 Mechanism of Action Clustering
  • 4.3.1 Catecholaminergic Pathway Modulators
  • 4.3.2 Dopamine Reuptake Inhibitors
  • 4.3.3 Norepinephrine Reuptake Inhibitors
  • 4.3.4 Dopamine-Norepinephrine Modulators
  • 4.3.5 Alpha-2 Adrenergic Receptor Agonists
  • 4.3.6 Triple Reuptake Inhibitors
  • 4.3.7 Novel CNS Targets
• 4.4 Novel versus Established Mechanisms
• 4.5 First-in-Class versus Best-in-Class Assessment
• 4.6 Modality Landscape
  • 4.6.1 Small Molecules
  • 4.6.2 Biologics
  • 4.6.3 RNA-based Therapeutics
  • 4.6.4 Cell and Gene Therapy Potential
  • 4.6.5 Digital Therapeutics and Combination Strategies
• 4.7 Innovation Heat Map
• 4.8 Mechanism-wise Competitive Benchmarking
• 4.9 Future Innovation Trends

5. Clinical Development Intelligence

• 5.1 Clinical Development Overview
• 5.2 Historical Clinical Development Trends
• 5.3 Clinical Trial Distribution by Phase
• 5.4 Trial Design Benchmarking
  • 5.4.1 Randomized Controlled Trials
  • 5.4.2 Open-label Studies
  • 5.4.3 Adaptive Trial Designs
  • 5.4.4 Extension Studies
• 5.5 Clinical Trial Sample Size Analysis
• 5.6 Primary and Secondary Endpoint Benchmarking
• 5.7 Trial Duration Analysis
• 5.8 Patient Recruitment Trends
• 5.9 Geographic Recruitment Patterns
• 5.10 Clinical Success Rate Analysis
• 5.11 Failure and Termination Analysis
• 5.12 Dropout Rate Assessment
• 5.13 Regulatory Trial Requirements
• 5.14 Pediatric Development Programs
• 5.15 Adult ADHD Clinical Development Trends

6. Global Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trials Landscape Report Segmentation Analysis

• 6.1 By Clinical Trial Phase
  • 6.1.1 Preclinical &Phase I
  • 6.1.2 Phase II
  • 6.1.3 Phase III
  • 6.1.4 Phase IV
• 6.3 By Drug Type
  • 6.3.1 Stimulants
  • 6.3.2 Non-Stimulants
• 6.4 By Therapeutic Modality
  • 6.4.1 Small Molecules
  • 6.4.2 Biologics
  • 6.4.3 RNA Therapeutics
  • 6.4.4 Digital and Combination Therapeutics
• 6.5 By Route of Administration
  • 6.5.1 Oral
  • 6.5.2 Transdermal
  • 6.5.3 Other Routes
• 6.5 By Sponsor Type
  • 6.5.1 Pharmaceutical & Biotech Companies
  • 6.5.2 Academic and Research Institutes
  • 6.5.3 Others

7. Probability of Success and Risk Analysis

• 7.1 Probability of Success Framework
• 7.2 Clinical Transition Probability Analysis
  • 7.2.1 Preclinical to Phase I
  • 7.2.2 Phase I to Phase II
  • 7.2.3 Phase II to Phase III
  • 7.2.4 Phase III to Approval
• 7.3 Historical Success Rate Benchmarking
• 7.4 Risk-adjusted Pipeline Analysis
• 7.5 Attrition Rate Assessment
• 7.6 Risk Matrix by Mechanism of Action
• 7.7 Risk Matrix by Development Stage
• 7.8 Regulatory Risk Assessment
• 7.9 Commercial Risk Assessment
• 7.10 Competitive Risk Assessment
• 7.11 Scenario-based Forecast Modeling
• 7.12 Probability-weighted Revenue Opportunity

8. Launch Timeline and Commercial Potential

• 8.1 Commercialization Outlook
• 8.2 Expected Approval Timeline
• 8.3 Expected Launch Timeline
• 8.4 Launch Sequencing Analysis
• 8.5 Pipeline Revenue Forecast
• 8.6 Peak Sales Opportunity Assessment
• 8.7 Market Share Capture Potential
• 8.8 Competitive Entry Timing
• 8.9 Brand Positioning Strategies
• 8.10 Pricing and Reimbursement Outlook
• 8.11 Lifecycle Management Strategies
• 8.12 Long-term Commercial Outlook

9. Competitive Pipeline Landscape

• 9.1 Competitive Landscape Overview
• 9.2 Pipeline Concentration Analysis
• 9.3 Company-wise Pipeline Strength Assessment
• 9.4 Leader versus Challenger Positioning
• 9.5 Innovation Leadership Matrix
• 9.6 Clinical Advancement Scorecard
• 9.7 Mechanism Leadership Analysis
• 9.8 Late-stage Competitive Positioning
• 9.9 Emerging Biotech Landscape
• 9.10 Strategic Benchmarking Framework

10. Geographic Analysis

• 10.1 North America
  • 10.1.1 Clinical Trial Activity
  • 10.1.2 Regulatory Environment
  • 10.1.3 Innovation Ecosystem
  • 10.1.4 Major Sponsors
• 10.2 Europe
  • 10.2.1 Clinical Trial Activity
  • 10.2.2 Regulatory Environment
  • 10.2.3 Innovation Ecosystem
  • 10.2.4 Major Sponsors
• 10.3 Asia-Pacific
  • 10.3.1 Clinical Trial Activity
  • 10.3.2 Regulatory Environment
  • 10.3.3 Innovation Ecosystem
  • 10.3.4 Major Sponsors
• 10.4 Latin America
  • 10.4.1 Clinical Trial Activity
  • 10.4.2 Regulatory Environment
  • 10.4.3 Innovation Ecosystem
  • 10.4.4 Major Sponsors
• 10.5 Middle East and Africa
  • 10.5.1 Clinical Trial Activity
  • 10.5.2 Regulatory Environment
  • 10.5.3 Innovation Ecosystem
  • 10.5.4 Major Sponsors

11. Key Countries Analysis

• 11.1 United States
  • 11.1.1 Clinical Trial Activity
  • 11.1.2 Regulatory Timelines
  • 11.1.3 Key Sponsors
  • 11.1.4 Future Outlook
• 11.2 Canada
  • 11.2.1 Clinical Trial Activity
  • 11.2.2 Regulatory Timelines
  • 11.2.3 Key Sponsors
  • 11.2.4 Future Outlook
• 11.3 Germany
  • 11.3.1 Clinical Trial Activity
  • 11.3.2 Regulatory Timelines
  • 11.3.3 Key Sponsors
  • 11.3.4 Future Outlook
• 11.4 United Kingdom
  • 11.4.1 Clinical Trial Activity
  • 11.4.2 Regulatory Timelines
  • 11.4.3 Key Sponsors
  • 11.4.4 Future Outlook
• 11.5 France
  • 11.5.1 Clinical Trial Activity
  • 11.5.2 Regulatory Timelines
  • 11.5.3 Key Sponsors
  • 11.5.4 Future Outlook
• 11.6 Italy
  • 11.6.1 Clinical Trial Activity
  • 11.6.2 Regulatory Timelines
  • 11.6.3 Key Sponsors
  • 11.6.4 Future Outlook
• 11.7 Spain
  • 11.7.1 Clinical Trial Activity
  • 11.7.2 Regulatory Timelines
  • 11.7.3 Key Sponsors
  • 11.7.4 Future Outlook
• 11.8 China
  • 11.8.1 Clinical Trial Activity
  • 11.8.2 Regulatory Timelines
  • 11.8.3 Key Sponsors
  • 11.8.4 Future Outlook
• 11.9 Japan
  • 11.9.1 Clinical Trial Activity
  • 11.9.2 Regulatory Timelines
  • 11.9.3 Key Sponsors
  • 11.9.4 Future Outlook
• 11.10 India
  • 11.10.1 Clinical Trial Activity
  • 11.10.2 Regulatory Timelines
  • 11.10.3 Key Sponsors
  • 11.10.4 Future Outlook
• 11.11 South Korea
  • 11.11.1 Clinical Trial Activity
  • 11.11.2 Regulatory Timelines
  • 11.11.3 Key Sponsors
  • 11.11.4 Future Outlook
• 11.12 Australia
  • 11.12.1 Clinical Trial Activity
  • 11.12.2 Regulatory Timelines
  • 11.12.3 Key Sponsors
  • 11.12.4 Future Outlook
• 11.13 Brazil
  • 11.13.1 Clinical Trial Activity
  • 11.13.2 Regulatory Timelines
  • 11.13.3 Key Sponsors
  • 11.13.4 Future Outlook
• 11.14 Mexico
  • 11.14.1 Clinical Trial Activity
  • 11.14.2 Regulatory Timelines
  • 11.14.3 Key Sponsors
  • 11.14.4 Future Outlook
• 11.15 Saudi Arabia
  • 11.15.1 Clinical Trial Activity
  • 11.15.2 Regulatory Timelines
  • 11.15.3 Key Sponsors
  • 11.15.4 Future Outlook
• 11.16 South Africa
  • 11.16.1 Clinical Trial Activity
  • 11.16.2 Regulatory Timelines
  • 11.16.3 Key Sponsors
  • 11.16.4 Future Outlook

12. Deals and Investment Landscape

• 12.1 Overview of Strategic Transactions
• 12.2 Licensing Agreements
  • 12.2.1 Regional Licensing Deals
  • 12.2.2 Global Licensing Deals
• 12.3 Co-development and Co-commercialization Agreements
• 12.4 Mergers and Acquisitions
• 12.5 Joint Ventures and Strategic Alliances
• 12.6 Venture Capital Investments
• 12.7 Private Equity Investments
• 12.8 Public Financing Activities
• 12.9 Funding Trends by Development Stage
• 12.10 Investment Outlook
• 12.11 Strategic Implications for Developers

13. Future Outlook and Strategic Insights

• 13.1 Future Evolution of ADHD Therapeutics
• 13.2 Emerging Scientific Trends
• 13.3 Next-generation Mechanisms of Action
• 13.4 Competitive White Space Opportunities
• 13.5 Strategic Recommendations for Innovators
• 13.6 Long-term Market Outlook
• 13.7 Key Companies Profiled
  • 13.7.1 Takeda Pharmaceutical Company Limited
  • 13.7.2 Supernus Pharmaceuticals, Inc.
  • 13.7.3 Axsome Therapeutics, Inc.
  • 13.7.4 Otsuka Pharmaceutical Co., Ltd.
  • 13.7.5 Neos Therapeutics, Inc.
  • 13.7.6 Collegium Pharmaceutical, Inc.
  • 13.7.7 Tris Pharma, Inc.
  • 13.7.8 Novartis
  • 13.7.9 Zevra Therapeutics
  • 13.7.10 Eli Lilly
• 13.8 Strategic Outlook for Stakeholders
• 13.9 Future Investment Priorities
• 13.10 Analyst Conclusions

14. Methodology and Data Framework

• 14.1 Research Objectives
• 14.2 Scope of the Report
• 14.3 Data Collection Framework
• 14.4 Pipeline Asset Inclusion Criteria
• 14.5 Clinical Trial Database Sources
  • 14.5.1 ClinicalTrials.gov
  • 14.5.2 EU Clinical Trials Information System (CTIS)
  • 14.5.3 Company Pipeline Disclosures
  • 14.5.4 Regulatory Filings and Public Documents
• 14.6 Pipeline Validation Methodology
• 14.7 Probability of Success Modeling Methodology
• 14.8 Commercial Forecasting Framework
• 14.9 Competitive Benchmarking Methodology
• 14.10 Limitations and Assumptions
• 14.11 Glossary of Terms and Abbreviations